Will Roche up its $44B ante for Genentech?

It didn't take long for two salient facts to emerge this morning from the headlines about Roche's willingness to fork over close to $44 billion for all the shares of Genentech it doesn't already own. First, Roche isn't valuing Genentech high enough. That $89 a share offer may well get pushed to the mid-90s. And that gets us to point two: Genentech's startling success on the cancer side of the business will likely offer enormous financial clout to an expansive Roche. Genentech has been rapidly pointing its pipeline programs in a number of new directions, and that also would be particularly attractive to a company like Roche, which can use valuable euros to buy out U.S. assets.

Analysts are also pumping up the synergy theme here as well. But that line may not play so well with Genentech's rank-and-file workers, who will be wondering how the company will be streamlined after a merger.

- see this release from Roche
- read the report from Forbes

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.